TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01024439

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: transumbilical single incision laparoscopic appendicectomy
Description: Patients will undergo transumbilical single incision laparoscopic appendicectomy. A single incision is made on umbilicus within the margin of umbilical skin ring. Peritoneal cavity is entered by open method and the fascia layer can be extended up to 2.5cm in length. A single incision laparoscopic device (Olympus) will be inserted. Conventional laparoscopic instruments will be used. Umbilical fascia will be closed by PDS-1 J-shape needle. Marcain 0.5% should be infiltrated into the fascial layers as well as the skin layers with dosage up to 20ml. The umbilicus is reconstructed by interrupted 3-0 nylon by tacking the skin onto the fascia layers.~Three non-transparent dressings will be placed as if conventional laparoscopic appendicectomy has been done.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional laparoscopic appendicectomy
Description: Patients will undergo conventional laparoscopic appendicectomy. A 10-mm subumbilical port will be inserted by open method. Two 5-mm working ports will be inserted under laparoscopic view at patient's left lower quadrant and suprapubic area. Umbilical fascia will be closed by PDS-1 J-shape needle.~Local anaesthetic agent , Marcain 0.5% should be infiltrated into the fascial layers as well as the skin layers with dosage up to 20ml. All skin wound will be approximated with 3-0 nylon interrupted stitches and covered with non-transparent dressings.
Study: NCT02522806

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: endometrial biopsy
Description: Endometrial biopsy (EB) between J17 and J22 of previous ovarian hyperstimulation cycle
Study: NCT00005856

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study: NCT00473356

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: receive amino acid supplement
Description: Receive amino acid supplement
Study: NCT02973893

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VF001-DP LD
Description: VF001-DP contains parts of normal vitronectin and Insulin-like growth factor 1 (IGF-I) combined in a single protein.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VF001-DP HD
Description: VF001-DP contains parts of normal vitronectin and Insulin-like growth factor 1 (IGF-I) combined in a single protein.
Study: NCT04281992

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AUP1602-C
Description: AUP1602-C is topically applied on chronic wounds and covered by wound dressing.
Study: NCT02812732

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: DOSE HPV
Description: The primary goals of the DOSE HPV intervention are to 1) change clinician HPV vaccine recommendations and responses to hesitant parents, and 2) support systems changes to improve the vaccination process. The first four sessions follow a standardized curriculum, while the last three sessions include development and implementation of tailored activities designed to meet individual practice needs.~Sessions 1 and 2 generate motivation for the project through feedback of vaccination rates (Session 1) and education on HPV disease (Session 2). Brief Negotiated Interview (BNI) skills are taught in Sessions 3\&4. Action Plans are developed in Session 5. Sessions 6\&7, which follow a standard quality improvement format: plan-do-study-act (PDSA) cycles.
Study: NCT02328443

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: itraconazole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rifampicin
Study: NCT03257085

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low-carbohydrate, high-fat
Description: Participants following low-carbohydrate, high-fat diet for 8 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-carbohydrate, moderate-fat
Description: Participants following high-carbohydrate, moderate-fat diet (UK dietary guidelines) for 8 weeks.
Study: NCT04066166

Intervention type: DIAGNOSTIC_TEST
Intervention: Palpation
Description: All healthy subjects palpated
Study: NCT03587649

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]MNI-1126
Description: Florbetapir PET imaging will be completed in all healthy volunteers and AD subjects as part of the screening procedures.~DaTscan SPECT imaging will be completed in those PDsubjects who have not previously had DaTscan imaging as part of the screening procedures.
Study: NCT03905486

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin 300mg
Description: Group 1: will receive pregabalin as a monotherapy. Pregabalin will be administered according to the treatment recommendations for fibromyalgia in the package insert \[Pfizer Inc., 2012\] starting by 50 mg twice daily increasing to 300 mg twice daily according to the efficacy and tolerability for 3 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Combined pregabalin 300mg and milancipran 100mg
Description: Group 2: will receive a combined pregabalin and milancipran. Pregabalin will be administered as group 1, while milancipran will be administered according to the treatment recommendations for fibromyalgia, starting by 50 mg once daily for 1 week then increased to reach 100 mg daily (50 mg twice daily) based on efficacy and tolerability for 3 month.
Study: NCT02702817

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen
Description: pale blue oval tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: pale blue oval tablets with no active ingredients, identical in appearance to naproxen intervention
Study: NCT03663803

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief theory-based health promotion intervention (group-based)
Description: The intervention is depicted using a PaT Plot in the published paper: Juul, L et al. Effectiveness of a brief theory-based health promotion intervention among adults at high risk of type 2 diabetes: One-year results from a randomised trial in a community setting. Primary Care Diabetes 1 0 ( 2 0 1 6 ) 111-120.
Study: NCT01578694

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Magnetic Resonance Imaging (MRI)
Description: T1 rho MRI is a modified pulse sequence from the standard T1 sequence used in the clinical MRI.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Magnetic Resonance Imaging (MRI)
Description: T1 rho MRI is a modified pulse sequence from the standard T1 sequence used in the clinical MRI.
Study: NCT03299907

Intervention type: DIAGNOSTIC_TEST
Intervention: Spirometry

Intervention type: DIAGNOSTIC_TEST
Intervention: Spirometry
Study: NCT02219945

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 5 min exhaled breath sampling with soft nose clamp
Description: study participants are requested to quietly sit and allow exhaled breath to be sampled through mouth piece breathing with nose clamp during 5 min while electronic data are collected in the device and later downloaded on a laptop pc

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 5 min exhaled breath sampling with soft nose clamp
Description: study participants are requested to quietly sit and allow exhaled breath to be sampled through mouth piece breathing with nose clamp during 5 min while electronic data are collected in the device and later downloaded on a laptop pc

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 5 min exhaled breath sampling with soft nose clamp
Description: study participants are requested to quietly sit and allow exhaled breath to be sampled through mouth piece breathing with nose clamp during 5 min while electronic data are collected in the device and later downloaded on a laptop pc

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 5 min exhaled breath sampling with soft nose clamp
Description: study participants are requested to quietly sit and allow exhaled breath to be sampled through mouth piece breathing with nose clamp during 5 min while electronic data are collected in the device and later downloaded on a laptop pc

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 5 min exhaled breath sampling with soft nose clamp
Description: study participants are requested to quietly sit and allow exhaled breath to be sampled through mouth piece breathing with nose clamp during 5 min while electronic data are collected in the device and later downloaded on a laptop pc

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 5 min exhaled breath sampling with soft nose clamp
Description: study participants are requested to quietly sit and allow exhaled breath to be sampled through mouth piece breathing with nose clamp during 5 min while electronic data are collected in the device and later downloaded on a laptop pc
Study: NCT01355081

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vortioxetine
Description: Vortioxetine tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vortioxetine
Description: Vortioxetine tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Vortioxetine placebo
Study: NCT02193178

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: comfilcon A Toric
Description: Contact lenses
Study: NCT01122147

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: chamomilla tincture mouthwash
Description: The patient is directed to mouth wash chamomilla tincture lightly three times a day,ten drops for each time,until ulcers completely heal

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo mouthwash
Description: The patient is directed to use placebo mouthwash three times a day, ten drops for each time,until the ulcers completely heal
Study: NCT05083299

Intervention type: DRUG
Intervention: Sarpogrelate
Description: Anpl-one SR
Study: NCT02328690

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Binaural Beat Technology
Description: A phenomenon when two nearly similar frequencies (between 30-1000 hertz \[Hz\]) are presented to each ear and the brain detects the difference between the two sounds. These two sounds are processed in the superior olivary nucleus of each hemisphere of the brain. This integration of brain hemispheres produces a frequency that in turn affects the reticular activating system which alters the electrical potentials of the thalamus and cerebral cortex changing brainwave frequency.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Binaural Beat Technology
Description: A phenomenon when two nearly similar frequencies (between 30-1000 hertz \[Hz\]) are presented to each ear and the brain detects the difference between the two sounds. These two sounds are processed in the superior olivary nucleus of each hemisphere of the brain. This integration of brain hemispheres produces a frequency that in turn affects the reticular activating system which alters the electrical potentials of the thalamus and cerebral cortex changing brainwave frequency.
Study: NCT02011204

Intervention type: DEVICE
Intervention: Electrical impedance myography (EIM)
Description: In EIM, high-frequency alternating electrical current is applied to localized areas of muscle via surface electrodes and the consequent surface voltage patterns analyzed.~EIM is very sensitive to the compositional and structural elements of muscle. Data from both human subjects and animal disease models, including ALS, spinal muscular atrophy (SMA), and Duchenne muscular dystrophy (DMD), show that EIM may be sensitive to a variety of pathological states. It is anticipated that EIM will thus likely be able to assist in quantifying the severity of the disease affecting various muscle groups as well as in measuring changes in the disease over time.

Intervention type: DEVICE
Intervention: Electrical impedance myography (EIM)
Description: In EIM, high-frequency alternating electrical current is applied to localized areas of muscle via surface electrodes and the consequent surface voltage patterns analyzed.~EIM is very sensitive to the compositional and structural elements of muscle. Data from both human subjects and animal disease models, including ALS, spinal muscular atrophy (SMA), and Duchenne muscular dystrophy (DMD), show that EIM may be sensitive to a variety of pathological states. It is anticipated that EIM will thus likely be able to assist in quantifying the severity of the disease affecting various muscle groups as well as in measuring changes in the disease over time.

Intervention type: DEVICE
Intervention: Electrical impedance myography (EIM)
Description: In EIM, high-frequency alternating electrical current is applied to localized areas of muscle via surface electrodes and the consequent surface voltage patterns analyzed.~EIM is very sensitive to the compositional and structural elements of muscle. Data from both human subjects and animal disease models, including ALS, spinal muscular atrophy (SMA), and Duchenne muscular dystrophy (DMD), show that EIM may be sensitive to a variety of pathological states. It is anticipated that EIM will thus likely be able to assist in quantifying the severity of the disease affecting various muscle groups as well as in measuring changes in the disease over time.
Study: NCT02344992

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BioChaperone insulin lispro
Description: Single dose of 0.2 U/kg body weight injected subcutaneously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Humalog®
Description: Single dose of 0.2 U/kg body weight injected subcutaneously
Study: NCT00653471

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Microcapmicro-stream device with Smart CapnoLine Plus
Description: nasal oxygen mask tested to determine accuracy of endtidal CO2 monitoring

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Microcapmicro-stream device with Smart CapnoLine Plus
Description: nasal oxygen mask tested to determine accuracy of endtidal CO2 monitoring

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Microcapmicro-stream device with Smart CapnoLine Plus
Description: nasal oxygen mask tested to determine accuracy of endtidal CO2 monitoring

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Microcap micro-stream device with CapnoLine
Description: CO2 measured via nasal cannula

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Microcap micro-stream device with CapnoLine
Description: CO2 measured via nasal cannula

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Microcap micro-stream device with CapnoLine
Description: CO2 measured via nasal cannula

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TG-920 main-stream device (Nihon Kohden, Tokyo, Japan).
Description: CO2 measured via nasal cannula

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TG-920 main-stream device (Nihon Kohden, Tokyo, Japan).
Description: CO2 measured via nasal cannula

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TG-920 main-stream device (Nihon Kohden, Tokyo, Japan).
Description: CO2 measured via nasal cannula
Study: NCT00948519

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser + ICG
Description: ICG arm- will be defined as local application on a pledget soaked with ICG with a concentration of 200µg, upon removal of the pledget a NIR diode laser set at 6W with light emittance introduced intranasally with a 30mm diffuser fiber capable of radiating light circumferentially allowing the light energy to reach all treatable areas. Laser will be activated for 180 seconds. Assuming an approximate radius of the nasal cavity is 3mm, energy density will be around 200J/cm². Treatment will be repeated twice, 5-7 day apart. Cultures will be collected at the end of all treatments

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laser only
Description: same only without ICG
Study: NCT04250051

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Given SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivosidenib
Description: Given PO
Study: NCT02268500

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Influenza vaccine
Description: Influenza vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Influenza vaccine
Description: Influenza vaccine
Study: NCT04164771

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic training and Moringa Oleifera
Description: Aerobic exercises/training refers to any type of rhythmic, continuous physical activities that use large group of muscles like walking, running, cycling, and swimming consuming additional amount of energy while Moringa Oleifera a plant from the family Moringacea, its products are used as a health supplement introduced in Africa and south Asian countries to cure many diseases and improve health status

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic training and Moringa Oleifera
Description: Aerobic exercises/training refers to any type of rhythmic, continuous physical activities that use large group of muscles like walking, running, cycling, and swimming consuming additional amount of energy while Moringa Oleifera a plant from the family Moringacea, its products are used as a health supplement introduced in Africa and south Asian countries to cure many diseases and improve health status

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic training and Moringa Oleifera
Description: Aerobic exercises/training refers to any type of rhythmic, continuous physical activities that use large group of muscles like walking, running, cycling, and swimming consuming additional amount of energy while Moringa Oleifera a plant from the family Moringacea, its products are used as a health supplement introduced in Africa and south Asian countries to cure many diseases and improve health status
Study: NCT04137393

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: brushing
Description: mechanical and chemical plaque removal

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: brushing
Description: mechanical and chemical plaque removal
Study: NCT05052164

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gluten-free nutrition plan + exercise group
Description: Menopausal or post-menopausal celiac women will follow a physical exercise program 3/4 times per week and their dietary intake will be gluten-free isocaloric

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gluten-free nutrition plan group
Description: Menopausal or post-menopausal celiac women will follow a gluten-free isocaloric dietary program

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator: Celiac controls group
Description: Menopausal or post-menopausal celiac women in whom all the tests were measured but they did not perform an intervention program with physical exercise or special follow-up of an adapted dietary-nutritional program
Study: NCT03802370

Intervention type: PROCEDURE
Group type: OTHER
Intervention: connective tissue grafting by Dome Technique
Description: The dome technique addresses the placement of the CT, as it is layered over the implant and takes the shape of an inverted dome
Study: NCT03458871

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 4-week TTNS home-based protocol
Description: 4-week TTNS home-based protocol. Electrodes 2 inch by 2 inch will be placed according to anatomic landmarks, with the negative electrode behind the internal malleolus and the positive electrode 10cm superior to the negative electrode, verified with rhythmic flexion of the toes secondary to stimulation of the flexor digitorum and hallicus brevis. The intensity level will be set to the amperage immediately under the threshold for motor contraction. If there is not contraction seen, maximal tolerable intensity will be used.~In addition, if the patient perceives pain, the intensity will be lowered until comfortable.~Stimulation frequency of 10 Hz and pulse width of 200ms in continuous mode will be used.
Study: NCT03415997

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iohexol
Description: Iodinated contrast media

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iohexol
Description: Iodinated contrast media
Study: NCT00910364

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Exercise
Study: NCT03688373

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: Each intervention will contain a 60-minute psycho-education session (PE) and two 60-minute exposure sessions (EX), conducted by a mental health professional together with a master student in psychology, who are both weekly supervised by a CBT certified psychologist. In the first (PE) session, participants learn about anxiety, specific phobias and exposure. During this session they will create a fear hierarchy (1 relating to least fearful and 10 indicating most fearful situation), formulate their cognition about the feared object or situation and determine what they want to achieve during treatment (e.g. goal situation). The next two sessions consist of exposure exercises in either big or small steps.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: Each intervention will contain a 60-minute psycho-education session (PE) and two 60-minute exposure sessions (EX), conducted by a mental health professional together with a master student in psychology, who are both weekly supervised by a CBT certified psychologist. In the first (PE) session, participants learn about anxiety, specific phobias and exposure. During this session they will create a fear hierarchy (1 relating to least fearful and 10 indicating most fearful situation), formulate their cognition about the feared object or situation and determine what they want to achieve during treatment (e.g. goal situation). The next two sessions consist of exposure exercises in either big or small steps.
Study: NCT00709553

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: midazolam

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: midazolam

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZD4054
Description: ZD4054 10 mg od
Study: NCT03255148

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: Syntocinon nasal spray

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo nasal spray